Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Published byBranden Dean Modified over 5 years ago

Similar presentations

Presentation on theme: "Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA."— Presentation transcript:

1 Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. (A) Plot demonstrating the relationship between HER2 mRNA levels (from RNA sequencing analysis) and HER2 copy number (from GISTIC analysis) for individual breast cancer cases, where sufficient data were available for analysis. Data were derived from, and plotted through, cbioportal.org. Blue dots represent individual HER2 wild-type cases, and orange dots represent individual HER2 mutant cases. (B) Plot demonstrating the relationship between HER2 protein levels (from reverse phase protein array analysis) and HER2 copy number (from GISTIC analysis) for individual breast cancer cases. Data were derived from, and plotted through, cbioportal.org. Blue dots represent individual HER2 wild-type cases, and orange dots represent individual HER2 mutant cases. GISTIC, Genomic Identification of Significant Targets in Cancer; TCGA, The Cancer Genome Atlas. Claire M Connell, and Gary J Doherty ESMO Open 2017;2:e000279 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA."

Similar presentations

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Mammogram images (A, B) indicate an irregular mass in the upper outer left breast. Ultrasound of the left breast (C) shows this to be a solid, hypoechoic.

Mammogram images (A, B) indicate an irregular mass in the upper outer left breast. Ultrasound of the left breast (C) shows this to be a solid, hypoechoic.
(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.

(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.
KDM1B Expression in Richardson Breast 2

KDM1B Expression in Richardson Breast 2
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, in comparison with the corresponding.

The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, in comparison with the corresponding.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
Relationship between Genotype and Phenotype

Relationship between Genotype and Phenotype
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
Comparison of the LL95%CI rule to PE rules with similar behaviour, when the true HR is different from the design HR: %acceptance of maximal relative benefit,

Comparison of the LL95%CI rule to PE rules with similar behaviour, when the true HR is different from the design HR: %acceptance of maximal relative benefit,
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Similar presentations

Ads by Google